Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07599813 is registered in ClinicalTrials.gov with Apollo Therapeutics Ltd as lead sponsor.

NCT NCT07599813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07599813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
Lead sponsor
Apollo Therapeutics Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
May 28, 2026
Completion date
April 30, 2028
Enrollment
280 (estimated)
Sites
85

Conditions

As the registry lists them; a condition with its own page is linked.

atopic, atopic dermatitis, dermatitis, dermatitis, atopic, dermatologic disease, eczema, eczema atopic dermatitis, eczema, atopic